The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ELCC 2021 | Targeting RET in lung cancer

Name: Targeting RET in lung cancer
Uploaded: 2021-03-22T00:00:00Z
Duration: 1 min 45 s
Description: Federico Cappuzzo, MD, PhD, AUSL della Romagna, Ravenna, Italy, outlines therapeutic options for the treatment of patients with RET-positive lung cancer, highlighting the use of selpercatinib and pralsetinib in advanced disease. Dr Cappuzzo also discusses the importance of screening patients for RET rearrangements. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.

Federico Cappuzzo • 22 Mar 2021

ELCC 2021

Lung Cancer Non-Small Cell Lung Cancer Pralsetinib Selpercatinib

Federico Cappuzzo, MD, PhD, AUSL della Romagna, Ravenna, Italy, outlines therapeutic options for the treatment of patients with RET-positive lung cancer, highlighting the use of selpercatinib and pralsetinib in advanced disease. Dr Cappuzzo also discusses the importance of screening patients for RET rearrangements. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.